McN-3495, a new compound unrelated structurally to the sulfonylureas or phenformin, has been found to produce a hypoglycemic effect in nondiabetic rats, dogs, mice, and monkeys. The minimum effective dose of McN-3495 that lowers fasting blood glucose and improves glucose tolerance was found to be about 2.5 to 5 mg. per kilogram, per os, except in fasted monkeys, in which a tenfold greater potency was observed. When McN-3495 was given repeatedly for three to five days, no tolerance to the hypoglycemic activity occurred and no changes in other biochemical parameters were observed. In addition to being three to four times more potent than tolbutamide, McN-3495 also differs from the sulfonylureas in lowering blood glucose concentrations of streptozotocin-diabetic rats and db/db mice, and, moreover, oral administration to normal fasted dogs did not produce the characteristic rise in insulin concentrations observed with tolbutamide. Furthermore, unlike the biguanides, McN-3495 can lower dog and rat fasting blood glucose concentrations and can improve glucose tolerance whether the glucose is administered orally or parenterally. However, McN-3495, as phenformin, fails to work in totally depancreatized dogs.
Skip Nav Destination
Article navigation
Original Contributions|
August 01 1978
A Pharmacologic Profile of McN-3495 [N-(1-methyl-2-pyrrolidinylidene)-N' -phenyl-1-pyrrolidinecarboximidamide], A New, Orally Effective Hypoglycemic Agent
Gene F Tutwiler, PhD;
Gene F Tutwiler, PhD
Endocrinology and Metabolism Group, Biochemistry Department, McNeil Laboratories Inc.
Fort Washington, PA 19034
Search for other works by this author on:
Thomas Kirsch;
Thomas Kirsch
Endocrinology and Metabolism Group, Biochemistry Department, McNeil Laboratories Inc.
Fort Washington, PA 19034
Search for other works by this author on:
Gary Bridi
Gary Bridi
Endocrinology and Metabolism Group, Biochemistry Department, McNeil Laboratories Inc.
Fort Washington, PA 19034
Search for other works by this author on:
Address reprint requests to Dr. Tutwiler.
Citation
Gene F Tutwiler, Thomas Kirsch, Gary Bridi; A Pharmacologic Profile of McN-3495 [N-(1-methyl-2-pyrrolidinylidene)-N' -phenyl-1-pyrrolidinecarboximidamide], A New, Orally Effective Hypoglycemic Agent. Diabetes 1 August 1978; 27 (8): 856–867. https://doi.org/10.2337/diab.27.8.856
Download citation file:
17
Views